Evidence map›Paper›PMID 31297829›Full record

ArticleJournal of surgical oncology2019

Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.

Emelia Stuart, Sudeep Banerjee, Jorge de la Torre, Yu Wang, Norman Scherzer, Adam M Burgoyne, Lisa Parry, Paul T Fanta, Sonia Ramamoorthy, Jason K Sicklick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Gastrointestinal Stromal Tumor: New Insights for a Multimodal Approach.Surgical oncology clinics of North America · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emelia StuartSchool of Medicine, University of California, San Diego, California.
Sudeep BanerjeeDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, California.
Jorge de la TorreDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, California.
Yu WangLife Raft Group, Wayne, New Jersey.
Norman ScherzerLife Raft Group, Wayne, New Jersey.
Adam M BurgoyneSchool of Medicine, University of California, San Diego, California.
Lisa ParrySchool of Medicine, University of California, San Diego, California.
Paul T FantaSchool of Medicine, University of California, San Diego, California.
Sonia RamamoorthySchool of Medicine, University of California, San Diego, California.
Jason K SicklickSchool of Medicine, University of California, San Diego, California.ORCID http://orcid.org/0000-0003-4403-0271

Funding

Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal TumorR01CA226803 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2023
$2.1M
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GISTK08CA168999 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2014 to 2018
$888k
Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor SyndromeR21CA192072 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2016 to 2017
$399k
NCI NIH HHS K08 CA168999NCI NIH HHS R01 CA226803NCI NIH HHS R21 CA192072NIH HHS K08CA168999NIH HHS R01CA226803NIH HHS R21CA192072
6 · The paper itself

Abstract

introductionRectal gastrointestinal stromal tumor (GIST) is rare and comprises about 3% of GIST.

methodsRegistry data was collected by the Life Raft Group June 1976 to November 2017. All patients had a histologic GIST diagnosis. Demographic, clinicopathologic, and clinical outcome data were patient reported. Recurrence-free survival (RFS) was analyzed using the Kaplan-Meier method and Cox regression analysis.

resultsOf 1798 patients in the database, 48 had localized rectal GIST (2.7%). Patients were frequently male (58.3%) and non-Hispanic whites (58.3%). Median age at diagnosis was 52 years. Most patients (77%) were diagnosed in the imatinib era (2001 to current). Over half (54.2%) of the cohort had mutation testing and all profiled tumors possessed KIT mutations (exon 9: 7.7%, exon 11: 88.5%, and exon 13: 3.8%). Most evaluable patients (26/28; 92.9%) had high-risk disease (modified NIH criteria) and nearly all patients (95.8%) received imatinib. Median follow-up was 8.8 years (range, 0.3-30.7) and overall RFS was 8.0 years (95% CI, 2.9-13.1). Thirty-two percent (12/37) of patients in the post-imatinib era developed recurrent disease. Diagnosis in the imatinib era was associated with improved RFS (HR = 0.22, 95% CI, 0.08-0.62; P = .004) in the multivariable model.

conclusionWe find that disease recurrence remains prevalent in one-third of patients treated during the imatinib-era.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsFemaleFollow-Up StudiesGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansImatinib MesylateInternational AgenciesMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesAntineoplastic AgentsImatinib Mesylategastrointestinal stromal tumorimatinibrectal masssubmucosal tumor

Identifiers

PMID31297829
PMCPMC6699886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.